I'm a PhD candidate in Health Policy, with a concentration in Ethics, at Harvard University.

My dissertation explores the ethical questions raised by high-cost health technologies (including but not limited to orphan drugs for rare diseases) and the strain they put on public health care budgets. The first paper argues that public insurers are justified in paying more per QALY for orphan drugs, not on account of the diseases’ rarity, but because of their severity. The second paper is a qualitative analysis of small-group deliberation sessions conducted in Alberta, Canada. The aim is to understand how citizens conceptualize severity of illness, and how severity interacts with the size of the patient population in citizens’ views on priority setting. The third paper discusses the idea of opportunity cost as applied to public health care systems.

I've served as a teaching fellow in undergraduate courses in health care policy and health economics and in graduate courses in public health ethics and research ethics, and in 2015-2016 was a Graduate Fellow at the Edmond J. Safra Center for Ethics.

CV